AU Patent

AU2021246889A1 — An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS)

Assigned to Nerre Therapeutics Ltd · Expires 2022-10-13 · 4y expired

What this patent protects

This invention relates to the new use of neurokinin-1(NK-1) receptor antagonists for treating sepsis, septic shock, systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS). The invention further rela…

USPTO Abstract

This invention relates to the new use of neurokinin-1(NK-1) receptor antagonists for treating sepsis, septic shock, systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS). The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists and combinations with one or more therapeutic agents, for such uses.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021246889A1
Jurisdiction
AU
Classification
—
Expires
2022-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Nerre Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.